menu search

CLGN / COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 SECOND QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 SECOND QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
-  Conference call to be held on Thursday, August 24, 2023 at 10:00 a.m. U.S. EDT - REHOVOT, Israel, Aug. 9, 2023 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced that it will report financial results for the second quarter of 2023 on Thursday, August 24, 2023, before the market open. Read More
Posted: Aug 9 2023, 09:02
Author Name: PRNewsWire
Views: 102429

CLGN News  

CollPlant Biotechnologies Ltd. (CLGN) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 24, 2023

CollPlant Biotechnologies Ltd. (CLGN) Q2 2023 Earnings Call Transcript

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN ) Q2 2023 Earnings Conference Call August 24, 2023 10:00 AM ET Company Participants Dory Kurowski - Invest more_horizontal

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 SECOND QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

By PRNewsWire
August 9, 2023

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 SECOND QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

-  Conference call to be held on Thursday, August 24, 2023 at 10:00 a.m. U.S. EDT - REHOVOT, Israel, Aug. 9, 2023 /PRNewswire/ -- CollPlant Biotechno more_horizontal

CollPlant Biotechnologies Ltd. (CLGN) Q4 2022 Earnings Call Transcript

By Seeking Alpha
March 29, 2023

CollPlant Biotechnologies Ltd. (CLGN) Q4 2022 Earnings Call Transcript

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN ) Q4 2022 Earnings Conference Call March 29, 2023 10:00 AM ET Company Participants Dory Kurowski - LifeSci more_horizontal

CollPlant: Expanding End-Market Opportunities

By Seeking Alpha
February 12, 2023

CollPlant: Expanding End-Market Opportunities

Possesses only plant-based collagen product with multiple end-market opportunities. AbbVie relationship alone justifies the current valuation. more_horizontal


Search within

Pages Search Results: